Chemical, Biological, Radiological, and Nuclear (CBRN) Funding Activities

Project BioShield institutes a secure funding source for the purchase of critical medical countermeasures, such as vaccines, therapeutics, and diagnostics. Project BioShield authorizes $5.6 billion in funding over 10 years for the advanced development and purchase of priority medical countermeasures. The table below represents the Project BioShield procurement activities for medical countermeasures against chemical, biological, radiological and nuclear threats that OPHEMC is pursuing.

Procurement Tables

Chemical, Biological, Radiological and Nuclear Medical Countermeasures
Biological Threat Agent Medical Countermeasure
Radiological/Nuclear Threat Agent Medical Countermeasures

Medical Countermeasure (MCM) Acquisition-Related Activities

CHEMICAL, BIOLOGICAL, RADIOLOGICAL AND NUCLEAR (CBRN) THREAT AGENT MEDICAL COUNTERMEASURES

Chemical, Biological, Radiological and Nuclear Threats
Request for Information			Pre-Solicitation Notices			Contract Award(s) Date-Company
Number	Posted	Closed	Number	Posted	Closed
Medical Countermeasures to Address Chemical, Biological, Radiological and Nuclear Threats
RFI-06-03	9/14/06	10/31/06

BIOLOGICAL THREAT AGENT MEDICAL COUNTERMEASURES

Anthrax
For More Information on OPHEMC's Anthrax program, please see our Anthrax Medical Countermeasures Fact Sheet.
Request for Information			Pre-Solicitation Notices			Contract Award(s) Date-Company
Number	Posted	Closed	Number	Posted	Closed
Emergency Responder Anthrax Antimicrobial Kits
SS-HHS-BARDA-08-99	03/07/08	03/21/08
Medkits
			RFP-BARDA-08-12	01/25/08	2/08/08
Next-Generation rPA Anthrax Vaccine
			HHS-BARDA-08-01-SB	02/08/08	2/21/08
RFP-BARDA-08-15	02/12/08	5/29/08	SS-DHHS-BARDA-07-01	5/14/07	6/11/07
RFI ORDC-03-01	8/14/03	9/10/03	RFP DHHS-ORDC-04-01	3/11/04	4/23/04	12/19/06 - Contract with VaxGen, Inc. Terminated 11/4/04 - Contract Awarded to VaxGen Inc.
Anthrax Vaccine Adsorbed (AVA)
			2005-B-01696	11/04/04	11/20/04	5/6/05—BioPort Corporation
			200-2005-11811-01	11/3/05	11/18/2005	5/5/06—BioPort Corporation
			RFP-DHHS-OPHEMC-VB-07-02			9/26/07 – Emergent Biodefense Operations
Therapeutic Products for Inhalational Anthrax
RFI (Anthrax Therapeutics)	12/24/03	2/1/04	RFP 2004-N-01385	8/18/04	10/26/04	9/23/05 — Human Genome Sciences and Cangene Corporation
						6/19/06 - Human Genome Sciences
						7/28/06 - Cangene Corporation
Therapeutic Products for Inhalational Anthrax #2
RFI-ORDC-05-04	2/23/05	5/10/05

Botulism
For More Information on OPHEMC's Botulism program, please see our Botulism Medical Countermeasures Fact Sheet.
Request for Information			Pre-Solicitation Notices			Contract Award(s) Date-Company
Number	Posted	Closed	Number	Posted	Closed
Botulinum Heptavalent Antitoxin
			2004-N-01183	9/14/04	10/3/04	6/1/2006—Cangene Corporation

Smallpox
For More Information on OPHEMC's Smallpox program, please see our Smallpox Medical Countermeasures Fact Sheet.
Request for Information			Pre-Solicitation Notices			Contract Award(s) Date-Company
Number	Posted	Closed	Number	Posted	Closed
Modified Vaccinia Ankara (MVA)
RFI ORDC-03-01	8/14/03	9/10/03	RFP DHHS-ORDC-VB-05-06	8/15/05	10/3/05	6/4/07 - Bavarian Nordic

RADIOLOGICAL / NUCLEAR THREAT AGENT MEDICAL COUNTERMEASURES

Medical Countermeasures for Radiological/Nuclear Incidents
Request for Information			Pre-Solicitation Notices			Contract Award(s) Date-Company
Number	Posted	Closed	Number	Posted	Closed
Physical and Biological Dosimetry Techniques and Devices Useful in Initial Triage After Radiologic and Nuclear Events
RFI-BARDA-08-21A
Therapeutics to Treat Neutropenia and Thrombocytopenia Associated with the Acute Radiation Syndrome (ARS)
DHHS-SOURCES-SOUGHT-ARS-MAY-2007	05/30/07	06/29/07	HHS-BARDA-08-10	2/29/08
RFI ORDC-05-01	10/19/04	12/20/04	RFP DHHS-ORDC-DDA-05-12	12/9/05	2/23/06
RFI ORDC-05-01A	5/20/2005	11/1/05	Draft RFP	11/18/05
			3/7/2007 - RFP-DHHS-ORDC-DDA-05-12 Canceled
Acquisition of Ca DTPA and Zn DTPA to Support a Public Health Emergency Response to a Radiological or Nuclear Event
			RFP-DHHS-ORDC-DDA-05-10	9/14/05	9/29/05	2/13/06—Akorn, Inc.
Pediatric Formulation (Liquid) Potassium Iodide (KI)
			SS-DHHS-ORDC-05-01	12/17/04	1/3/05	3/18/05—Fleming & Company Pharmaceuticals
						2/8/06—Fleming & Company Pharmaceuticals